- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04932564
Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant
Pilot Study of Leflunomide as First Line Therapy for Musculoskeletal GVHD
Graft versus host disease (GVHD) is a well-known complication of allogeneic transplant. In GVHD, the cells of the donor attack the patient's tissues and cause damage. It can affect any organ or system of the body. In a proportion of patients, it affects the joints and muscles. This is known as musculoskeletal GVHD. The standard treatment of musculoskeletal GVHD is steroids. However, these are usually needed for prolonged periods, and cause a large number of additional problems in transplant patients.
Leflunomide is a drug which has been used for several years in diseases like rheumatoid arthritis (RA). RA is an auto-immune disorder. The biological mechanisms underlying RA and musculoskeletal GVHD are quite similar. Hence it is likely that leflunomide may work in musculoskeletal GVHD also. The investigator have previously used leflunomide in a few patients with musculoskeletal GVHD and have found it to be extremely effective. Also, it was very safe (unlike steroids). Yet another advantage is that it is fairly cheap.
The purpose of the current study is to study the efficacy and safety of leflunomide in patients with musculoskeletal GVHD in a prospective way.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The curative potential of allogeneic hematopoietic stem cell transplantation (allo-HCT) is hampered by acute and chronic graft-versus-host disease (GVHD). Although chronic GVHD (cGVHD) can affect any organ / system in the body, commonly affected are skin, oral cavity, eyes, liver, joints and fascia, and lungs. Involvement of these can occur alone or concurrently, and these lead to a significant negative impact on the patient's quality of life. Musculoskeletal involvement in chronic GVHD (mGVHD) can have varied presentations like fasciitis, myositis, arthritis, etc. The basic pathogenesis of mGvHD closely mimics autoimmune disorders like rheumatoid arthritis, systemic sclerosis, systemic lupus, etc.
The treatment goals of mGvHD include improvement or stabilisation of manifestations, limitation of long-term treatment related toxicities, improvement in functional capacity and quality of life. Corticosteroids, the standard frontline treatment, are typically administered for a median of 2 to 3years, leading to substantial morbidity. An effort to decrease corticosteroid doses has led to their use in combination with other drugs, such as cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, rituximab, etanercept, ruxolotinib, imatinib, ibrutinib, ECP (extra corporeal photopheresis), methotrexate etc, in frontline or second-line settings. All these drugs have been used with far and few responses but with significant treatment related toxicity and costs. As far as musculoskeletal GVHD is concerned, the British guidelines recommend corticosteroids as first line treatment and rituximab as second line option. However, the morbidity associated with long term steroid use warrants a quest for use of non-steroid therapies to be used in 1st line setting for chronic GVHD.
Leflunomide has been used in rheumatoid arthritis. At our centre, the investigator have previously used leflunomide for patients with musculoskeletal GVHD and found it to be effective and safe. Leflunomide is relatively cheap and potentially more effective compared to other more expensive alternatives. If proven to be effective in a larger cohort of patients, this drug could become the standard first line agent in this setting.
With this, the investigator have planned to carry out this study to assess the efficacy of leflunomide in musculoskeletal GVHD post allogeneic stem cell transplant.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sachin Punatar, MD, DM
- Phone Number: 5096 02227405000
- Email: drsachin_punatar@yahoo.in
Study Locations
-
-
Maharashtra
-
Navi Mumbai, Maharashtra, India, 410210
- Recruiting
- Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer
-
Contact:
- Sachin Punatar, DM
- Phone Number: 5096 022-24705000
- Email: drsachin_punatar@yahoo.in
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing to give written informed consent
- Patients diagnosed with musculoskeletal mGvHD based on 2014 NIH consensus criteria (with diagnosis confirmed by biopsy only if clinically required).
- Willing and able to comply with all study requirements, including treatment, and periodic assessments.
Exclusion Criteria:
- Patients with known hypersensitivity to leflunomide especially previous Steven Johnson syndrome, toxic epidermal necrolysis after leflunomide.
- Pregnant females
- Patients with musculoskeletal manifestations explained by other potential causes ( (drugs, trauma, etc).
- Patients with calculated glomerular filtration rate (GFR) <30ml/min at the time of screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Leflunomide Arm
Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.
This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
|
Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. The dosing for children will be as follows:
This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall objective response rate
Time Frame: Through study completion, an average of 2 years
|
Response will be defined as per the NIH 2014 consensus response criteria working group for mGvHD.
|
Through study completion, an average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to response
Time Frame: From date of start of leflunomide to date of first documented response, assessed up to 2 Years
|
The time required to achieve complete or partial response after treatment.
|
From date of start of leflunomide to date of first documented response, assessed up to 2 Years
|
Time to best response
Time Frame: From date of start of leflunomide to date of documented best response, assessed up to 2 Years
|
Time to best response will be recorded.
|
From date of start of leflunomide to date of documented best response, assessed up to 2 Years
|
Duration of response
Time Frame: From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
|
The duration of response will be calculated from the time of onset of objective response after initiation of treatment with leflunomide until the end of the follow-up, GVHD relapse, the development of new or the deterioration of pre-existing mGVHD symptoms, or the reinstitution of any additional agents to control the disease.
|
From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
|
Relapse rate
Time Frame: Through study completion, an average of 2 years
|
Relapse rate of mGVHD after stopping leflunomide will be recorded.
|
Through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sachin Punatar, MD, DM, Tata Memorial Centre
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 900643
- CTRI/2021/04/033214 (Registry Identifier: Clinical Trials Registry- India (CTRI))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Disease Other
-
Federal University of São PauloCompletedContracture | Disorder of Shoulder | Other Musculoskeletal DisorderBrazil
-
University of IowaNational Institute for Biomedical Imaging and Bioengineering (NIBIB); Colorado...CompletedSpinal Diseases | Tracheal Intubation Morbidity | Other Biomechanical Lesions of Cervical RegionUnited States
-
Pioneer Surgical Technology, Inc.WithdrawnLumbar Spinal Stenosis Secondary to Other Disease
-
Ankara Training and Research HospitalCompletedVitamin D Deficiency | Isotretinoin Adverse Reaction | Musculoskeletal Disease OtherTurkey
-
National Heart Centre SingaporeDuke-NUS Graduate Medical SchoolCompletedCardiovascular Disease OtherSingapore
-
Sunnybrook Health Sciences CentreRecruitingShoulder Arthropathy Associated With Other ConditionsCanada
-
Healthpoint HospitalUnknownShoulder Arthropathy Associated With Other ConditionsUnited Arab Emirates
-
Groupe Hospitalier Diaconesses Croix Saint-SimonRecruitingHip Arthropathy Associated With Other ConditionsFrance
-
Washington University School of MedicineCompletedShoulder Arthropathy Associated With Other ConditionsUnited States
-
Assiut UniversityNot yet recruitingShoulder Arthropathy Associated With Other Conditions
Clinical Trials on Leflunomide tablet
-
International Bio serviceNot yet recruiting
-
Astellas Pharma IncAstellas Pharma China, Inc.Terminated
-
PfizerNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States, Canada
-
University Hospital, LimogesUnknownBullous PemphigoidFrance
-
Changzheng-CinkateTerminatedViremia | ViruriaUnited States
-
Ashford and St. Peter's Hospitals NHS TrustCompleted
-
SanofiCompletedArthritis, RheumatoidRomania, Portugal, Czech Republic, Italy, Korea, Republic of
-
University Hospital, Basel, SwitzerlandRecruiting
-
Assiut UniversityCompleted